Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results.
Article in Zhurnal nevrologii i psikhiatrii im S S Korsakova (January 2023)